References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-216-8-9-23

nogr-2398

Research Article

ПЕРЕДОВАЯ СТАТЬЯ

LEADING ARTICLE

Энтерогепатоцентризм как основа психосоматической патологии человека

Enterohepatocentrism as the basis of human psychosomatic pathology

https://orcid.org/0000-0001-8736-5851

Лазебник

Л. Б.

Lazebnik

L. B.

leonid.borisl@gmail.com

https://orcid.org/0000-0002-8844-2465

Туркина

С. В.

Turkina

S. V.

noemail@neicon.ru

Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный медико-стоматологический университет им. А. И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияA. I. Yevdokimov Moscow State University of Medicine and DentistryRussian Federation

Федеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияVolgograd State Medical UniversityRussian Federation

2023

09102023

08923

2023

Лазебник Л.Б., Туркина С.В.

Lazebnik L.B., Turkina S.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2398

Микробиота кишечника регулирует важнейшие процессы метаболизма и физиологии хозяина. Понимание формирования взаимосвязей между микробиомом кишечника, печенью и другими органами в физиологических условиях, а также при воздействии повреждающих микробиоту факторов, дает важные сведения о патофизиологии не только заболеваний печени, но и сложном уровне коммуникации и роли микробиома в осях кишечник-печень-мозг, кишечник-печень-почка, кишечник-печень-легкие и кишечник-печень-сердце.

The gut microbiota regulates critical processes in host metabolism and physiology. Understanding the formation of relationships between the gut microbiome, liver, and other organs under physiological conditions, as well as under the influence of microbiota-damaging factors, provides important insights into the pathophysiology of not only liver diseases, but also the complex level of communication and the role of the microbiome in the gut-liver-brain, gut-liver-kidney, gut-liver-lung, and gut-liver-heart axes.

микробиота кишечникаструктура энтерогепатоцентризмаось кишечникпеченьоси кишечник-печень-мозгкишечник-печень-почкакишечник-печень-легкиекишечник-печень-сердце

gut microbiotastructure of enterohepatocentrismgut-liver axisgut-liver-brain axisgut-liver-kidney axisgut-liver-lung axisgut-liver-heart axis

References1

Ayyıldız F., Akbulut G., Karaçil Ermumcu M. Ş., Acar Tek N. Emotional and intuitive eating: an emerging approach to eating behaviours related to obesity. J Nutr Sci. 2023 Feb 13;12: e19. doi: 10.1017/jns.2023.11.

Malyutina EA, Tokareva SV. [Effects of stress and gastrointestinal disorders on the progression of hemodynamic disorders in patients with cardiovascular diseases (literature review)]. Journal of New Medical Technologies. e-edition. 2023;17(1):30-39.Russian. Available from: http://www.medtsu.tula.ru/VNMT/Bulletin/E2023-1/1-5.pdf doi: 10.24412/2075-4094-2023-1-1-5. EDN XBLWRI @@ Малютина Е. А., Токарева С. В. Влияние стресса и желудочно-кишечных расстройств на прогрессирование гемодинамических нарушений у больных с сердечно-сосудистыми заболеваниями (обзор литературы). Вестник новых медицинских технологий. Электронное издание. 2023;17(1):30-39. doi: 10.24412/2075-4094-2023-1-1-5.

Mechnikov I. I. Essays on human nature. M.5 Publishing House of the Academy of Sciences of the USSR, 1961, 289 р. (in Russ.)@@ Мечников И. И. Этюды о природе человека. М.5 Изд-во Академии Наук СССР, 1961, 289 с.

Shenderov B. A. Diet influence on the intestinal microbiota in patients with metabolic syndrome. Bulletin of Rehabilitation Medicine. 2016;1(71):21. (in Russ.)@@ Шендеров Б. А. Микроэкологическая эпигенетика стресса, заболеваний, здо-ровья и долголетия. Вестник восстановительной медицины. - 2016. - Т. 1. - №. 71. - С. 21.

Oleskin А.V., Shenderov B. A. Probiotics, Psychobiotics, and Metabiotics: Problems and Prospects. Physical and rehabilitation medicine, medical rehabilitation. 2020;2(3):233-243. doi: 10.36425/rehab25811.@@ Олескин А. В., Шендеров Б. А. Пробиотики, психобиотики и метабиотики: проблемы и перспективы. Физическая и реабилитационная медицина, медицинская реабилитация. 2020;2(3):233-243. doi: 10.36425/rehab25811.

Grandclément C., Tannières M., Moréra S., Dessaux Y., Faure D. Quorum quenching: role in nature and applied developments. FEMS Microbiol Rev. 2016 Jan;40(1):86-116. doi: 10.1093/femsre/fuv038.

Di Ciaula A., Baj J., Garruti G., Celano G. et al. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med. 2020;9(8):2648. doi: 10.3390/jcm9082648.

Di Tommaso N., Gasbarrini A., Ponziani F. R.Intestinal Barrier in Human Health and Disease.Int J Environ Res Public Health. 2021;18(23):12836. doi: 10.3390/ijerph182312836.

Vlasov A.A., Salikova S. P., Golovkin N. V., Grinevich V. B.Intestinal Microbial-tissue Complex and Chronic Heart Failure (part 1): Pathogenesis. Rational Pharmacotherapy in Cardiology. 2021;17(3):462-469. (In Russ.) doi: 10.20996/1819-6446-2021-06-12.@@ Власов А. А., Саликова С. П., Головкин Н. В., Гриневич В. Б. Микробно-тканевой комплекс кишечника и хроническая сердечная недостаточность (часть 1): патогенез. Рациональная Фармакотерапия в Кардиологии. 2021;17(3):462-469. doi: 10.20996/1819-6446-2021-06-12.

Ivashkin V.T., Ivashkin K. V. Human microbiome, applied to clinical practice. Ross z gastroenterol gepatol koloproktol. 2017; 27(6):4-13. (in Russ.) doi: 10.22416/1382-4376-2017-27-6-4-13.@@ Ивашкин В. Т., Ивашкин К. В. Микробиом человека в приложении к клинической практике. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(6):4-13. doi: 10.22416/1382-4376-2017-27-6-4-13.

Yudina Yu.V., Korsunsky A. A., Aminova A. I., Abdullaeva G. D., Prodeus A. P. Gut microbiota as a separate body system.Russian Journal of Evidence-Based Gastroenterology. 2019;8(4):36-43. (In Russ.) doi: 10.17116/dokgastro2019804-05136.@@ Юдина Ю. В., Корсунский А. А., Аминова А. И., Абдуллаева Г. Д., Продеус А. П. Микробиота кишечника как отдельная система организма. Доказательная гастроэнтерология. 2019;8(4):36-43. doi: 10.17116/dokgastro2019804-05136.

Fan Y., Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021 Jan;19(1):55-71. doi: 10.1038/s41579-020-0433-9.

Konturek P.C., Harsch I. A., Konturek K., Schink M., et al. Gut (-) Liver Axis: How Do Gut Bacteria Influence the Liver? Med. Sci. 2018;6:79. doi: 10.3390/medsci6030079.

Hou K., Wu Z. X., Chen X. Y. et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022 Apr 23;7(1):135. doi: 10.1038/s41392-022-00974-4.

Burger E., Araujo A., López-Yglesias A., Rajala M. W., Geng L., Levine B., Hooper L. V., Burstein E., Yarovinsky F. Loss of Paneth Cell Autophagy Causes Acute Susceptibility to Toxoplasma gondii-Mediated Inflammation. Cell Host Microbe. 2018;23(2):177-190.e4. doi: 10.1016/j.chom.2018.01.

Adak A., Khan M. R. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019 Feb;76(3):473-493. doi: 10.1007/s00018-018-2943-4.

Ashida H., Ogawa M., Kim M., Mimuro H, Sasakawa C. Bacteria and host interactions in the gut epithelial barrier. Nat Chem Biol. 2011;8(1):36-45. doi: 10.1038/nchembio.741.

Round J.L., Mazmanian S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009 May;9(5):313-23. doi: 10.1038/nri2515.

Wu L., Luo Y. Bacterial Quorum-Sensing Systems and Their Role in Intestinal Bacteria-Host Crosstalk. Front Microbiol. 2021; 12:611413. doi: 10.3389/fmicb.2021.611413.

Hooper L.V., Gordon J. I.Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115-8. doi: 10.1126/science.1058709.

Tkachenko E. I., Lazebnik L. B. Connective tissue and microbiota. The facets of interaction in norm and pathology. Experimental and Clinical Gastroenterology. 2022;207(11): 17-25. (In Russ.) doi: 10.31146/1682-8658-ecg-207-11-17-25.@@ Ткаченко Е. И., Лазебник Л. Б. Соединительная ткань и микробиота. Грани взаимодействия в норме и патологии. Экспериментальная и клиническая гастроэнтерология. 2022;207(11): 17-25. doi: 10.31146/1682-8658-ecg-207-11-17-25.

Shreiner A.B., Kao J. Y., Young V. B. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015 Jan;31(1):69-75. doi: 10.1097/MOG.0000000000000139.

Sicard J.F., Le Bihan G., Vogeleer P., Jacques M., Harel J.Interactions of Intestinal Bacteria with Components of the Intestinal Mucus. Front Cell Infect Microbiol. 2017 Sep 5;7:387. doi: 10.3389/fcimb.2017.00387.

Vancamelbeke M., Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821-834. doi: 10.1080/ 17474124.2017.1343143.

Paradis T., Bègue H., Basmaciyan L., Dalle F., Bon F. Tight Junctions as a Key for Pathogens Invasion in Intestinal Epithelial Cells.Int J Mol Sci. 2021;22(5):2506. doi: 10.3390/ijms22052506.

Ohtani N., Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019 Mar 1;3(4):456-470. doi: 10.1002/hep4.1331.

Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003.

Horowitz A., Chanez-Paredes S.D., Haest X., Turner J. R. Paracellular permeability and tight junction regulation in gut health and disease. Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):417-432. doi: 10.1038/s41575-023-00766-3.

Simanenkov V.I., Maev I. V., Tkacheva O. N., Alekseenko S. A., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (in Russ.) doi: 10.15829/1728-8800-2021-2758.@@ Симаненков В. И., Маев И. В., Ткачева О. Н., Алексеенко С. А., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021; 20 (1):2758. doi: 10.15829/1728-8800-2021-2758.

McDonald B.D., Jabri B., Bendelac A. Diverse developmental pathways of intestinal intraepithelial lymphocytes. Nat Rev Immunol. 2018;18(8):514-525. doi: 10.1038/s41577-018-0013-7.

Owaga E., Hsieh R. H., Mugendi B., Masuku S., Shih C. K., Chang J. S. Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases.Int J Mol Sci. 2015;16(9):20841-58. doi: 10.3390/ijms160920841.

Spadoni I., Zagato E., Bertocchi A., Paolinelli R. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015 Nov 13;350(6262):830-4. doi: 10.1126/science.aad0135.

Bushyhead D., Quigley E. M.M. Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management. Gastroenterology. 2022 Sep;163(3):593-607. doi: 10.1053/j.gastro.2022.04.002.

Collins S.L., Stine J. G., Bisanz J. E., Okafor C. D., Patterson A. D. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023 Apr;21(4):236-247. doi: 10.1038/s41579-022-00805-x.

Gong Z., Zhou J., Zhao S., Tian C., Wang P., Xu C., Chen Y., Cai W., Wu J. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis. Oncotarget. 2016;7(51):83951-83963. doi: 10.18632/oncotarget.13796.

Zhu C., Fuchs C. D., Halilbasic E., Trauner M. Bile acids in regulation of inflammation and immunity: friend or foe? Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):25-31. Epub 2016 Jul 29. PMID: 27586800.

Dossa A.Y., Escobar O., Golden J., Frey M. R., Ford H. R., Gayer C. P. Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. Am J Physiol Gastrointest Liver Physiol. 2016 Jan 15;310(2): G81-92. doi: 10.1152/ajpgi.00065.2015.

Yokota A., Fukiya S., Islam K. B., Ooka T., Ogura Y., Hayashi T., Hagio M., Ishizuka S. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes. 2012 Sep-Oct;3(5):455-9. doi: 10.4161/gmic.21216.

De Fabiani E., Mitro N., Gilardi F., Galmozzi A., Caruso D., Crestani M. When food meets man: the contribution of epigenetics to health. Nutrients. 2010;2(5):551-71. doi: 10.3390/nu2050551.

Wang D.Q., Portincasa P., Tso P. Transintestinal cholesterol excretion: A secondary, nonbiliary pathway contributing to reverse cholesterol transport. Hepatology. 2017 Oct;66(4):1337-1340. doi: 10.1002/hep.29341.

Chen Y., Wu S., Tian Y. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest. 2018;98(1):7-14. doi: 10.1038/labinvest.2017.95.

You S, Cui AM, Hashmi SF, Zhang X, et al. Dysregulation of bile acids increases the risk for preterm birth in pregnant women. Nat Commun. 2020;11(1):2111. doi: 10.1038/s41467-020-15923-4.

Cai J., Rimal B., Jiang C., Chiang J. Y.L., Patterson A. D. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther. 2022 Sep;237:108238. doi: 10.1016/j.pharmthera.2022.108238.

Perino A., Schoonjans K. Metabolic Messengers: bile acids. Nat Metab. 2022 Apr;4(4):416-423. doi: 10.1038/s42255-022-00559-z.

Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015 Jan;148(1):30-6. doi: 10.1053/j.gastro. 2014.10.042.

Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011 Jan;91(1):151-75. doi: 10.1152/physrev.00003.2008.

Kamm D.R., McCommis K. S. Hepatic stellate cells in physiology and pathology. J Physiol. 2022 Apr;600(8): 1825-1837. doi: 10.1113/JP281061.

Brenner D.A., Kisseleva T., Scholten D., Paik Y. H. et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1): S17. doi: 10.1186/ 1755-1536-5-S1-S17.

Nakatani K., Kaneda K., Seki S., Nakajima Y. Pit cells as liver-associated natural killer cells: morphology and function. Med Electron Microsc. 2004;37(1):29-36. doi: 10.1007/s00795-003-0229-9.

Peng H., Wisse E., Tian Z. Liver natural killer cells: subsets and roles in liver immunity. Cell Mol Immunol. 2016 May;13(3):328-36. doi: 10.1038/cmi.2015.96.

Martínez-Chantar M.L., Delgado T. C., Beraza N. Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease. Front Immunol. 2021 Feb 18;12:640869. doi: 10.3389/fimmu.2021.640869.

Salzberger W., Martrus G., Bachmann K. et al. Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. PLoS One. 2018 Jul 20;13(7): e0201170. doi: 10.1371/journal.pone.0201170.

Keating S.E., Zaiatz-Bittencourt V., Loftus R. M., Keane C., Brennan K., Finlay D. K., Gardiner C. M. Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells. J Immunol. 2016 Mar 15;196(6): 2552-60. doi: 10.4049/jimmunol.1501783.

Zaneveld J.R., McMinds R., Vega Thurber R. Stress and stability: applying the Anna Karenina principle to animal microbiomes. Nat Microbiol. 2017 Aug 24;2:17121. doi: 10.1038/nmicrobiol.2017.121.

Kobayashi T., Iwaki M., Nakajima A., Nogami A., Yoneda M. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.Int J Mol Sci. 2022 Oct 2;23(19):11689. doi: 10.3390/ijms231911689.

Malaguarnera G., Giordano M., Nunnari G., Bertino G., Malaguarnera M. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol. 2014 Nov 28;20(44):16639-48. doi: 10.3748/wjg.v20.i44.16639.

Tytgat H.L.P., Nobrega F. L., van der Oost J., de Vos W. M. Bowel Biofilms: Tipping Points between a Healthy and Compromised Gut? Trends Microbiol. 2019 Jan;27(1):17-25. doi: 10.1016/j.tim.2018.08.009.

Deng Z., Luo X. M., Liu J., Wang H. Quorum Sensing, Biofilm, and Intestinal Mucosal Barrier: Involvement the Role of Probiotic. Front Cell Infect Microbiol. 2020 Sep 25;10:538077. doi: 10.3389/fcimb.2020.538077.

Chelakkot C., Ghim J., Ryu S. H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018 Aug 16;50(8):1-9. doi: 10.1038/s12276-018-0126-x.

Plaza-Díaz J., Solís-Urra P., Rodríguez-Rodríguez F., Olivares-Arancibia J., Navarro-Oliveros M., Abadía-Molina F., Álvarez-Mercado A. I. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.Int J Mol Sci. 2020 Nov 7;21(21):8351. doi: 10.3390/ijms21218351.

Kaibysheva V.O., Zharova M. E., Filimendikova K. Yu., Nikonov E. L. Diseases associated with impaired composition of the intestinal microbiota. Doctor.Ru. 2021; 20(4): 40-45. (in Russ.) doi: 10.31550/1727-2378-2021-20-4-40-45.@@ Кайбышева В.О., Жарова М. Е., Филимендикова К. Ю., Никонов Е. Л. Заболевания, ассоциированные с нарушением состава микробиоты кишечника. Доктор.Ру. 2021; 20(4): 40-45. doi: 10.31550/1727-2378-2021-20-4-40-45.

Milosevic I., Vujovic A., Barac A., Djelic M., Korac M., Radovanovic Spurnic A., Gmizic I., Stevanovic O., Djordjevic V., Lekic N., Russo E., Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.Int J Mol Sci. 2019 Jan 17;20(2):395. doi: 10.3390/ijms20020395.

Yan S., Yin X. M. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res. 2021 Sep;5(3):151-163. doi: 10.1016/j.livres.2021.08.001.

Miele L., Marrone G., Lauritano C., Cefalo C., Gasbarrini A., Day C., Grieco A. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des. 2013;19(29):5314-24. PMID: 23432669.

Yu J., Marsh S., Hu J., Feng W., Wu C. The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract. 2016;2016:2862173. doi: 10.1155/2016/2862173.

Quigley E. M. Leaky gut - concept or clinical entity? Curr Opin Gastroenterol. 2016 Mar;32(2):74-9. doi: 10.1097/MOG.0000000000000243.

Wieland A., Frank D. N., Harnke B., Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015 Nov;42(9):1051-63. doi: 10.1111/apt.13376.

Adams L.A., Anstee Q. M., Tilg H., Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017 Jun;66(6):1138-1153. doi: 10.1136/gutjnl-2017-313884.

Li W., Liu J., Cai J., Zhang X. J., Zhang P., She Z. G., Chen S., Li H. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol. 2022 Feb;163:118-132. doi: 10.1016/j.yjmcc.2021.10.007.

Gehrke N., Schattenberg Jörn M. Metabolic Inflammation - A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? Gastroenterology. 2020;158:1929-1947.e6. doi: 10.1053/j.gastro.2020.02.020.

Shenderov B.A., Golubev V. L., Danilov A. B., Prishchepa A. V. Gut human microbiota and neurodegenerative diseases. Poliklinika. 2016;(1-1):7-13. (In Russ.)@@ Шендеров Б. А., Голубев В. Л., Данилов А. Б., Прищепа А. В. Кишечная микробиота человека и нейродегенеративные заболевания. Поликлиника 2016; 1-1: 7-13.

Kozhevnikov A.A., Raskina K. V., Martynova E. Yu. et al. The involvement of gut microbiota in the processes of metabolism, aging and perspectives of using available data in real clinical practice. RMJ. MEDICAL REVIEW. 2017, No. 2, pp. 98-105. (in Russ.)@@ Кожевников А. А., Раскина К. В., Мартынова Е. Ю. и др. Участие кишечной микробиоты в процессах метаболизма, старения и перспективы применения имеющихся данных в реальной клинической практике. РМЖ. МЕДИЦИНСКОЕ ОБОЗРЕНИЕ. 2017. № 2. С. 98-105.

Kharitonova L. A., Grigoriev K. I., Borzakova S. N. Human microbiote: how a new scientific paradigm changes medical practice. Experimental and Clinical Gastroenterology. 2019;161(1): 55-63. (In Russ.) doi: 10.31146/1682-8658-ecg-161-1-55-63.@@ Харитонова Л. А., Григорьев К. И., Борзакова С. Н. Микробиота человека: как новая научная парадигма меняет медицинскую практику. Экспериментальная и клиническая гастроэнтерология. 2019;161(1): 55-63. doi: 10.31146/1682-8658-ecg-161-1-55-63.

Ibragimova L.I., Kolpakova E. A., Dzagakhova A. V., Egshatyan L. V., Pokrovskaya E. V., Derevyanko O. S., Nikonova T. V. The role of the gut microbiota in the development of type 1 diabetes mellitus. Diabetes mellitus. 2021;24(1):62-69. (In Russ.) doi: 10.14341/DM10326.@@ Ибрагимова Л. И., Колпакова Е. А., Дзагахова А. В., Егшатян Л. В., Покровская Е. В., Деревянко О. С., Никонова Т. В. Роль микробиоты кишечника в развитии сахарного диабета 1 типа. Сахарный диабет. 2021;24(1):62-69. doi: 10.14341/DM10326.

Wiatrak B., Balon K., Jawień P., Bednarz D. et al. The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer’s Disease.Int J Mol Sci. 2022;23(9):4862. doi: 10.3390/ijms23094862.

Mulak A. Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer’s Disease. J Alzheimers Dis. 2021;84(2):461-477. doi: 10.3233/JAD-210608.

Young R.P., Hopkins R. J., Marsland B. The Gut-Liver-Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2016;54(2):161-9. doi: 10.1165/rcmb.2015-0250PS.

Giordano L., Mihaila S. M., Eslami Amirabadi H., Masereeuw R. Microphysiological Systems to Recapitulate the Gut-Kidney Axis. Trends Biotechnol. 2021;39(8):811-823. doi: 10.1016/j.tibtech.2020.12.001.

Raj D., Tomar B., Lahiri A., Mulay S. R. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease. Pharmacol Res. 2020; 152:104617. doi: 10.1016/j.phrs.2019.104617.

Evenepoel P., Poesen R., Meijers B. The gut-kidney axis. Pediatr Nephrol. 2017;32(11):2005-2014. doi: 10.1007/s00467-016-3527-x.

Rukavina Mikusic N. L., Kouyoumdzian N. M., Choi M. R. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch. 2020 Mar;472(3):303-320. doi: 10.1007/s00424-020-02352-x.

Mahmoodpoor F., Rahbar Saadat Y., Barzegari A., Ardalan M., Zununi Vahed S. The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother. 2017; 93:412-419. doi: 10.1016/j.biopha.2017.06.066.

Roager H.M., Licht T. R. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018 Aug 17;9(1):3294. doi: 10.1038/s41467-018-05470-4.

Ismaiel A., Dumitraşcu D. L. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne). 2019 Sep 13;6:202. doi: 10.3389/fmed.2019.00202.

Lin J., Kakkar V., Lu X. Essential Roles of Toll-Like Receptors in Atherosclerosis. Curr Med Chem. 2016;23(5): 431-54. doi: 10.2174/0929867323666151207111408.

Tang W.H., Wang Z., Levison B. S., Koeth R. A. et al.Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575-84. doi: 10.1056/NEJMoa1109400.

Tang W.H., Wang Z., Kennedy D. J., Wu Y., Buffa J. A., Agatisa-Boyle B., Li X. S., Levison B. S., Hazen S. L. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015 Jan 30;116(3):448-55. doi: 10.1161/CIRCRESAHA.116.305360.

Ma G., Pan B., Chen Y., Guo C., Zhao M., Zheng L., Chen B. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci Rep. 2017 Mar 2;37(2): BSR20160244. doi: 10.1042/BSR20160244.

Yang S., Li X., Yang F., Zhao R., Pan X., Liang J., Tian L., Li X., Liu L., Xing Y., Wu M. Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. Front Pharmacol. 2019 Nov 19;10:1360. doi: 10.3389/fphar.2019.01360.

Zhu W., Wang Z., Tang W. H.W., Hazen S. L. Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects. Circulation. 2017 Apr 25;135(17):1671-1673. doi: 10.1161/CIRCULATIONAHA.116.025338.

Konev Y. V., Lazebnik L. B. Metabolism of endotoxin in the body and its role in the process of involution. Clinical gerontology. 2009;15(1):39-46. (in Russ.)@@ Конев Ю. В., Лазебник Л. Б. Метаболизм эндотоксина в организме и его роль в процессе инволюции. Клиническая геронтология. - 2009. - Т. 15. - №. 1. - С. 39-46.

Konev Y. V., Lazebnik L. B. Role of endotoxin of intes- tinal microbiota in the pathogenesis of atherosclerosis. Therapy. 2015;(2):19-27. (in Russ.)@@ Конев Ю. В., Лазебник Л. Б. Роль эндотоксина кишечной микробиоты в патогенезе атеросклероза. Терапия. - 2015. - №. 2. - С. 19-27.

Jia X., Qi Y., Zheng R. et al. Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults. Front Cardiovasc Med. 2022 May 18;9:906396. doi: 10.3389/fcvm.2022.906396.

Kjeldsen E.W., Thomassen J. Q., Frikke-Schmidt R. HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jan;1867(1):159063. doi: 10.1016/j.bbalip.2021.159063.

The authors declare that there are no conflicts of interest present.